Oncolytics Biotech庐 Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech (NASDAQ: ONCY) held its Annual General Meeting (AGM) on August 8, 2025, with 37.42% of outstanding shares represented. The company successfully elected eight directors to its board, with approval rates ranging from 80.45% to 91.64%. The highest approval was received by Jared Kelly (91.64%), while Jonathan Rigby received the lowest support (80.45%).
Shareholders also approved additional resolutions, including fixing the board size at eight members and appointing auditors. The meeting results demonstrate strong shareholder support for the company's governance structure.
Oncolytics Biotech (NASDAQ: ONCY) ha tenuto la sua assemblea generale annuale (AGM) l'8 agosto 2025, con il 37,42% delle azioni in circolazione rappresentate. Sono stati eletti con successo otto amministratori, con tassi di approvazione compresi tra il 80,45% e il 91,64%. Il massimo sostegno 猫 stato ottenuto da Jared Kelly (91,64%), mentre Jonathan Rigby ha ricevuto il livello di supporto pi霉 basso (80,45%).
I soci hanno inoltre approvato ulteriori delibere, tra cui la conferma del consiglio in otto membri e la nomina dei revisori. I risultati evidenziano un solido sostegno degli azionisti alla struttura di governance della societ脿.
Oncolytics Biotech (NASDAQ: ONCY) celebr贸 su junta general anual (AGM) el 8 de agosto de 2025, con el 37,42% de las acciones en circulaci贸n representadas. La compa帽铆a eligi贸 con 茅xito a ocho consejeros, con tasas de aprobaci贸n que oscilaron entre el 80,45% y el 91,64%. Jared Kelly recibi贸 el mayor respaldo (91,64%), mientras que Jonathan Rigby obtuvo el apoyo m谩s bajo (80,45%).
Los accionistas tambi茅n aprobaron otras resoluciones, entre ellas fijar el tama帽o del consejo en ocho miembros y nombrar a los auditores. Los resultados reflejan un s贸lido apoyo de los accionistas a la estructura de gobierno de la compa帽铆a.
Oncolytics Biotech (NASDAQ: ONCY)電� 2025雲� 8鞗� 8鞚� 鞐半 欤检＜齑濏殞(AGM)毳� 臧滌禍頄堨溂氅� 氚滍枆欤检嫕鞚� 37.42%臧� 雽�響滊悩鞐堨姷雼堧嫟. 鞚挫偓須� 甑劚鞗� 8氇呾澊 氇憪 靹标车鞝侅溂搿� 靹犾瀯霅橃棃瓿� 鞀轨澑毳犾潃 80.45%鞐愳劀 91.64% 靷澊鞓�鞀惦媹雼�. 臧�鞛� 雴掛潃 歆�歆�毳� 氚涭潃 瓴冹潃 Jared Kelly(91.64%)鞓�瓿�, Jonathan Rigby電� 臧�鞛� 雮潃 歆�歆�(80.45%)毳� 氚涭晿鞀惦媹雼�.
欤检＜霌れ潃 鞚挫偓須� 攴滊毳� 8氇呾溂搿� 頇曥爼頃橁碃 臧愳偓鞚胳潉 靹犾瀯頃橂姅 霌� 於旉皜 鞎堦贝霌る弰 鞀轨澑頄堨姷雼堧嫟. 鞚措矆 鞚橁舶 瓴瓣臣電� 須岇偓鞚� 瓯半矂雱岇姢 甑“鞐� 雽�頃� 欤检＜霌れ潣 臧曧暅 歆�歆�毳� 氤挫棳欷嶋媹雼�.
Oncolytics Biotech (NASDAQ: ONCY) a tenu son assembl茅e g茅n茅rale annuelle (AGM) le 8 ao没t 2025, avec 37,42% des actions en circulation repr茅sent茅es. La soci茅t茅 a 茅lu avec succ猫s huit administrateurs, les taux d'approbation variant de 80,45% 脿 91,64%. Jared Kelly a obtenu la plus forte approbation (91,64%), tandis que Jonathan Rigby a re莽u le soutien le plus faible (80,45%).
Les actionnaires ont 茅galement approuv茅 d'autres r茅solutions, notamment le maintien du conseil 脿 huit membres et la nomination des commissaires aux comptes. Ces r茅sultats t茅moignent d'un solide soutien des actionnaires 脿 la gouvernance de la soci茅t茅.
Oncolytics Biotech (NASDAQ: ONCY) hielt am 8. August 2025 seine j盲hrliche Hauptversammlung (AGM) ab, bei der 37,42% der ausstehenden Aktien vertreten waren. Das Unternehmen w盲hlte erfolgreich acht Direktoren, mit Zustimmungsraten zwischen 80,45% und 91,64%. Die h枚chste Zustimmung erhielt Jared Kelly (91,64%), die niedrigste Jonathan Rigby (80,45%).
Die Aktion盲re stimmten zudem weiteren Beschl眉ssen zu, darunter die Festlegung der Vorstandsgr枚脽e auf acht Mitglieder und die Bestellung der Abschlusspr眉fer. Die Ergebnisse zeigen eine starke Unterst眉tzung der Aktion盲re f眉r die Governance-Struktur des Unternehmens.
- None.
- None.
On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:
Director | For | % | Withheld | % |
Patricia Andrews | 10,498,328 | 88.83听% | 1,320,714 | 11.17听% |
Deborah M. Brown | 10,115,110 | 85.58听% | 1,703,932 | 14.42听% |
闯补谤别诲听碍别濒濒测 | 10,830,605 | 91.64听% | 988,437 | 8.36听% |
Angela Holtham | 10,175,887 | 86.10听% | 1,643,155 | 13.90听% |
James T. Parsons | 10,172,958 | 86.07听% | 1,646,084 | 13.93听% |
Wayne Pisano | 10,148,894 | 85.87听% | 1,670,148 | 14.13听% |
Jonathan Rigby | 9,508,770 | 80.45听% | 2,310,272 | 19.55听% |
Bernd R. Seizinger | 10,269,441 | 86.89听% | 1,549,601 | 13.11听% |
In addition to the election of all nominees listed as directors in the management information circular, dated June 18, 2025,听Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year.
For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at听. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold"听tumors "hot"听through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit:听听or follow the Company on social media on 听and on X @.
Company Contact
Jon Patton
Director of IR & Communication
[email protected]听
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
[email protected]听
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
[email protected]听
Logo -
View original content to download multimedia:
SOURCE Oncolytics Biotech庐 Inc.
FAQ
What was the shareholder participation rate at Oncolytics Biotech's (ONCY) 2025 AGM?
Who received the highest approval rating among ONCY's director nominees in 2025?
How many directors were elected to Oncolytics Biotech's board in 2025?
What was the lowest approval rating received by an ONCY director nominee in 2025?
